Swiss biotechnology firm Speedel says that its collaborator Novartis is set to expand the clinical trial program of SPP100 (aliskiren; Rasilez/Tekturna) to study organ protection potential beyond the already shown powerful reduction of blood pressure. The long-term ASPIRE HIGHER study, now forms the largest and most far-reaching cardio-renal outcomes program worldwide.
The two new studies are to evaluate the organ protection potential of the first-in-class direct renin inhibitor SPP100 for the treatment of heart failure and prevention of cardiovascular disease in the elderly, a patient segment that is predicted to more than double between 2000 and 2030. A third trial already underway is studying cardio-renal outcomes in diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze